Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 21, 2026
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: September 09, 2025
A Response to the Letter to the Editor: "Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 31, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 28, 2025
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 21, 2025
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: June 26, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 10, 2024
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Journal: Clinical pharmacology and therapeutics
Published: June 16, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 21, 2022
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 02, 2021
Last Updated: 09/26/2026